Nobivac® DP PLUS
Redefining puppy protection.
A new era in parvovirus protection. Vaccinate earlier with more confidence than ever before.
The importance of early vaccination.
Young puppies are at high risk of contracting debilitating or fatal diseases. This is why early immunisation ensures protection and delivers peace of mind. Maternally derived antibodies (MDA) provide protection during the first weeks of a puppy’s life– but high levels of MDA can interfere with vaccination.Learn more
Infectious diseases in puppies.
Puppies need protection against canine distemper virus and canine parvovirus. Canine distemper virus mostly affects puppies and, in a case series drawn from practice records submitted to SAVSNET, nearly 40% of parvovirus cases presented in pups below 11 weeks of age.1Learn more
Studies demonstrate the efficacy of Nobivac® DP PLUS, including a 3 day onset of immunity to protect against canine parvovirus2 and the ability to overcome parvovirus associated maternally derived antibody from 4 weeks of age3.
Game-changing parvovirus protection.
parvovirus protection without MDA interference from 4 weeks of age
parvovirus protection with
a 3 day onset of immunity
Communicate with your clients about the importance of enhanced early disease protection
for their puppies.
Find an array of different materials for the main channels you use for client communications.
Nobivac® DP PLUS is a vaccine containing live attenuated canine distemper virus and live recombinant canine parvovirus. POM-V
Further information is available from the SPC, Datasheet or package leaflet. MSD Animal Health UK Limited.
Registered office Walton Manor, Walton, Milton Keynes MK7 7A J, UK. Registered in England & Wales no. 946942.
Advice should be sought from the medicine prescriber.
Use medicines responsibly.
1. CPV data set by SAVSNET for MSD Animal Health: 51 cases identified in SAVSNET database by free text search.
2. Study report Nobivac DP PLUS 001, MSD Animal Health.
3. Study report Nobivac DP PLUS 002, MSD Animal Health.